| Field | Specification |
|---|---|
| Organism | |
| Applications | |
| Tissue | |
| Disease | Derived from a lymph node metastasis of a female with nodular melanoma |
| Growth properties | |
| Biosafety level | |
| Product format | Frozen |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This melanoma cell line panel is unique from all other available melanoma cell lines as these cells have been raised under conditions that prevent phenotype switching. MM001/HBL is sensitive to TKI (Dasatinib, Sunitinib); (MM001-R (HBL-R) line with acquired resistance to TKI).
Key elements and design rationale
- Model identity: Acral Lentiginous Melanoma Cell Line - (HBL (MM001)) is supplied as a tumor cell line derived from Human lymph node.
- Growth properties: Adherent, proliferative melanocyte-like phenotype
- Growth conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. Ham's F10 Medium + 10% FBS(Regular*) + 2 mM L-Glutamine (G275) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. *Do not heat-inactivate
- Product format: Frozen, BSL-2
This cell-based model is generally used in cancer biology, phenotype comparison, and response profiling studies. Donor/background information is available for contextual interpretation.
Biological background
This cell line is applicable for high-throughput screening/Drug testing and 3D cell cultures. MM001/HBL is a Suitable transfection host and is tumorigenic: cells produce xenograft tumors when injected into immunocompromised mice. Note: This cell line should be cited in a scientific publication as: HBL (MM001). Additional cell lines from this panel: Cat. T8080 - Acral Lentiginous Melanoma Cell Line (HBL (MM001)) Cat. T8081 - Acral Lentiginous Melanoma Cell Line (MM011/LND1) Cat. T8082 - Lymph Node Metastasis SS Melanoma Cell Line (MM029) Cat. T8083 - Bladder Metastasis Nodular Melanoma Cell Line (MM031) Cat. T8084 - Lymph Node Metastasis Melanoma Cell Line (MM034) Cat. T8085 - Superficial Spreading Melanoma Cell Line (MM052) Cat. T8086 - Lymph Node Metastasis Melanoma Cell Line (MM057) Cat. T8087 - Lymph Node Metastasis SS Melanoma Cell Line (MM074) Cat. T8088 - Lymph Node Metastasis SS Melanoma Cell Line (MM165) Donor/background information provided for this product: Derived from a lymph node metastasis of a female with nodular melanoma.
Research relevance and current trends
- Cell-line models continue to be used for tumor phenotype comparison, pathway perturbation studies, and assay development in controlled in vitro systems.
- Engineered and subtype-defined tumor lines are often used to compare growth behavior, reporter output, and response patterns across matched experimental conditions.
- When metastatic or lineage features are described, investigators commonly interpret results alongside morphology, passage history, and culture environment.
Common research applications
- Cancer biology studies that compare proliferation-associated behavior, morphology, and pathway responses in vitro.
- Assay development for treatment response, reporter monitoring, or phenotype comparison under matched culture conditions.
- Side-by-side comparison of engineered versus parental background characteristics when relevant to the study design.
Changes in morphology, growth rate, viability, or reporter signal are typically interpreted together with passage history, culture matrix, and the specified growth conditions for the model.
Notes for experimental interpretation
- Morphology, doubling behavior, and reporter or marker output can shift with passage number, substrate choice, and medium composition; these variables should be recorded alongside experimental readouts.
- Matched controls such as parental cells, untreated cultures, or parallel cultures maintained under identical conditions help distinguish background effects from biology of interest.
Culture and product details
- Growth Conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. Ham's F10 Medium + 10% FBS(Regular*) + 2 mM L-Glutamine (G275) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. *Do not heat-inactivate
- Split Ratio: 1:3 to 1:8
—
🧊 Thawing Protocol
- Thaw cells quickly in a 37°C water bath while agitating gently (maximum 2 minutes). The vial cap should be kept above the water level to minimize the risk of contamination.
- Decontaminate the vial by spraying and wiping the exterior of the vial with 70% ethanol. From this point onwards, all operations should be strictly carried out inside a biological safety cabinet using aseptic conditions.
- Transfer the cell suspension into a 15ml sterile conical tube containing 5ml of pre-warmed, complete growth media. Centrifuge cells at 125xg for 5-7 minutes.
- Aspirate the supernatant without disturbing the cell pellet. Re-suspend the cell pellet in the recommended pre-warmed, complete growth media and dispense into a T25 culture flask.
- Incubate the cells at the recommended conditions.
🔬 Subculture Protocol
Cells are sensitive to trypsin; Gentle Dissociation Solution (TM080) is recommended for subculture procedures. Volumes given below are for a T75 flask; proportionally increase or decrease the volume as required per culture vessel size. Subculture cells once the culture vessel is 80% confluent.
- Aspirate the culture media, and add 2-3ml of pre-warmed Gentle Dissociation Solution (TM080) to the culture vessel.
- Observe the cells under a microscope to confirm detachment (typically within 2-10 minutes). Cells that are difficult to detach can be put in 37°C, for several minutes to facilitate detachment.
- Neutralize the Gentle Dissociation Solution (TM080) by adding an equal volume of the complete growth media into the culture vessel.
- Transfer the culture suspension into a sterile centrifuge tube, and centrifuge at 125xg for 5 minutes. The actual centrifuge duration and speed may vary depending on the cell type.
- Aspirate the supernatant, and re-suspend the pellet with pre-warmed fresh complete growth media. Add appropriate aliquots of the cell suspension to new culture vessels, as desired.
- Incubate the cells at the recommended conditions.
How should I handle live cells once I receive them?
Please refer to our Cell Handling and Thawing Guidelines for detailed instructions on receiving, thawing, and culturing live cells:
https://www.abmgood.com/immortalized-cells-documents.html
Following these guidelines will help ensure optimal cell viability and performance.
https://www.abmgood.com/immortalized-cells-documents.html
Following these guidelines will help ensure optimal cell viability and performance.
Why are these cells classified as biosafety level II?
We follow the CDC-NIH recommendations that all mammalian sourced products should be handled at the Biological Safety Level 2 to minimize exposure of potentially infectious products. This information can be found in 'Biosafety in Microbiological and Biomedical Laboratories' (1999). Your institution's Safety Officer or Technical Services will be able to make the call as to whether BioSafety Level I is possible with these cells at your site, if desired.
What is your warranty or return policy?
Our warranty and return policy is outlined in abm’s Terms and Conditions, including details on product quality, limitations, and claims.
Please refer to the following link for full information:
https://www.abmgood.com/terms
For additional questions, our Order team is happy to assist and can be reached at order@abmgood.com.
Please refer to the following link for full information:
https://www.abmgood.com/terms
For additional questions, our Order team is happy to assist and can be reached at order@abmgood.com.
How many times can cells divide?
The number of times cells can divide depends on the cell type:
Primary cells have a limited lifespan and will undergo a finite number of population doublings before entering senescence. The exact number varies by cell type and culture conditions.
Immortalized cell lines are capable of extended or indefinite proliferation under proper culture conditions, although growth characteristics may vary between lines.
Primary cells have a limited lifespan and will undergo a finite number of population doublings before entering senescence. The exact number varies by cell type and culture conditions.
Immortalized cell lines are capable of extended or indefinite proliferation under proper culture conditions, although growth characteristics may vary between lines.
Do I need Applied Cell Extracellular Matrix (G422) if I am using PriCoat™ flasks?
Please refer to the Growth Conditions section of your specific product page. This section will indicate whether Applied Cell Extracellular Matrix (G422), PriCoat™ flasks, or both are recommended for optimal cell attachment and growth, as requirements may vary by cell type.
Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.
Eves, P., Haycock, J., Layton, C., Wagner, M., Kemp, H., Szabo, M., Morandini, R., Ghanem, G., García-Borrón, J. C., Jiménez-Cervantes, C., & Mac Neil, S. (2003). Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. British journal of cancer, 89(10), 2004–2015. https://doi.org/10.1038/sj.bjc.6601349
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., Goydos, J., Haigh, J. J., Haupt, Y., Larue, L., Jochemsen, A., Shi, H., Moriceau, G., Lo, R. S., Ghanem, G., Shackleton, M., … Marine, J. C. (2012). MDM4 is a key therapeutic target in cutaneous melanoma. Nature medicine, 18(8), 1239–1247. https://doi.org/10.1038/nm.2863
Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Emond, A., Attias, M., Yang, W., Plourde, D., Su, J., Gimeno, M. G., Zhan, Y., Galán, A., Rzymski, T., Mazan, M., Masiejczyk, M., Faber, J., Khoury, E., … Del Rincón, S. V. (2021). Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. The Journal of clinical investigation, 131(8), e140752. https://doi.org/10.1172/JCI140752
Mauduit, D., Taskiran, I. I., Minnoye, L., de Waegeneer, M., Christiaens, V., Hulselmans, G., Demeulemeester, J., Wouters, J., & Aerts, S. (2021). Analysis of long and short enhancers in melanoma cell states. eLife, 10, e71735. https://doi.org/10.7554/eLife.71735
Porcelli, L., Guida, G., Quatrale, A. E., Cocco, T., Sidella, L., Maida, I., … Azzariti, A. (2015a). Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. Journal of Translational Medicine, 13(1). https://doi.org/10.1186/s12967-015-0385-4
Sabbah, M., Krayem, M., Najem, A., Sales, F., Miller, W., Del Rincon, S., Awada, A., Ghanem, G. E., & Journe, F. (2021). Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. Molecular cancer research : MCR, 19(7), 1221–1233. https://doi.org/10.1158/1541-7786.MCR-20-1040
Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., … Journe, F. (2023a). ATP1A1 Is a Promising New Target for Melanoma Treatment and Can Be Inhibited by Its Physiological Ligand Bufalin to Restore Targeted Therapy Efficacy. doi:https://doi.org/10.21203/rs.3.rs-3218478/v1
Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., Claerhout, S., Fiers, M., Journe, F., Ghanem, G. E., Herrmann, C., Halder, G., Marine, J. C., & Aerts, S. (2015). Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nature communications, 6, 6683. https://doi.org/10.1038/ncomms7683
Wouters, J., Kalender-Atak, Z., Minnoye, L., Spanier, K. I., De Waegeneer, M., Bravo González-Blas, C., Mauduit, D., Davie, K., Hulselmans, G., Najem, A., Dewaele, M., Pedri, D., Rambow, F., Makhzami, S., Christiaens, V., Ceyssens, F., Ghanem, G., Marine, J. C., Poovathingal, S., & Aerts, S. (2020). Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nature cell biology, 22(8), 986–998. https://doi.org/10.1038/s41556-020-0547-3
Zanna, P., Maida, I., Grieco, C., Guida, S., Turpin Sevilla, M. C., De Summa, S., Tommasi, S., Vena, G. A., Filotico, R., & Guida, G. (2013). Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins. Journal of biological regulators and homeostatic agents, 27(1), 131–141.
10%
OFF
20%
OFF
$50
OFF
FREE
SAMPLE
